Glenn Batchelder was most recently co-founder and CEO of Civitas Therapeutics, a pulmonary delivery company with a lead program for treating Parkinson’s disease that was acquired by Acorda Therapeutics. Prior to Civitas, he was the founding CEO of BIND Therapeutics (BIND), a leading nanotherapeutics company. Prior to BIND, Mr. Batchelder was the initial CEO of Acceleron Pharma (XLRN) an oncology and supportive care biotherapeutics company. Prior to Acceleron, Mr. Batchelder was Senior Vice President of Operations at Millennium Pharmaceuticals where he played an integral leadership role in the launch of VELCADE® and was responsible for the commercial supply chain and technical operations for INTEGRILIN®. Mr. Batchelder received a B.S. in chemical engineering from Lehigh in 1984 and serves on the Board of Directors of the Massachusetts Biotechnology Council.